Replies to post #8538 on Inovio Pharmaceuticals Inc (INO)

[cazual]

Yes, huge financial deal for INO!

Through the terms, Roche will make an upfront payment of $10 million to Inovio, and will also supply preclinical R&D support and payments for near-term regulatory milestones, together with payments upon reaching certain development and commercial milestones, potentially up to $412.5 million. Additional development milestone payments might also be made to Inovio should Roche pursues other indications with INO-5150 or INO-1800. Beyond that, Inovio may to receive up to double-digit tiered royalties on product sales.

ino-20130910
wallstcheatsheet.com/stocks/nokia-partners-with-mercedes-benz-over-smart-maps-2-other-hot-stocks-to-watch.html/3/

[Everywhereman]

I do not know the milestone structure, but it is a good guess that starting P1 will be one, and they are starting P1 by the end of the year. That should result in some sort of payment.

So it should turn in to a steady stream of money. My thought is this will cover all INO operations for the next 5 years (it could go longer, but I doubt it). Of course missing a milestone will cause problems. Also the company could grow fast enough to consume that money, but that is also another good sign.